生物制药公司Black Diamond Therapeutics, Inc.近日宣布，其研发的Silevertinib在针对EGFR突变非小细胞肺癌（EGFRm NSCLC）患者的一线治疗二期临床试验数据，已被选入2026年美国临床肿瘤学会（ASCO）年会进行口头报告。这项重要研究成果将于全球肿瘤学专家面前亮相，标志着该疗法在临床开发进程中取得关键进展。
生物制药公司Black Diamond Therapeutics, Inc.近日宣布，其研发的Silevertinib在针对EGFR突变非小细胞肺癌（EGFRm NSCLC）患者的一线治疗二期临床试验数据，已被选入2026年美国临床肿瘤学会（ASCO）年会进行口头报告。这项重要研究成果将于全球肿瘤学专家面前亮相，标志着该疗法在临床开发进程中取得关键进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.